NOW APPROVED

style
marigold
An icebreaker ship breaks through a landscape of icebergs that reflect the many prior challenges in treating mPDAC and targeting RAS, heading into an iceberg that reads "Revolutionizing mPDAC, Breaking Barriers."
REVOLUTIONIZING mPDAC BREAKING BARRIERS
See the data
https://www.revmed.com/pi/us-rasonque-pi.pdf

The first and only approved RAS(ON) multi-selective inhibitor1*

Redefining the standard of care (SOC) in metastatic pancreatic adenocarcinoma (mPDAC)1,2

RASolute 302 was a Phase 3 trial evaluating the efficacy and safety of RASONQUE monotherapy vs SOC combination chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma.1,2

*RASONQUE is an inhibitor of the RAS GTPase family. RASONQUE binds to cyclophilin A, resulting in a binary complex that binds to the active, GTP-bound state of RAS.
identifier
sub-hero

Unprecedented overall survival (OS) was observed in patients, regardless of RAS mutation status1,3

Primary endpoints1,2

OS
(RAS G12 POPULATION)
RASONQUE
(n=228)
SOC combination chemotherapy*
(n=231)
mOS
13.2 months
6.6 months
HR=0.40 (95% CI: 0.30, 0.54)†; p<0.0001‡
PFS
(RAS G12 POPULATION)
RASONQUE
(n=228)
SOC combination chemotherapy*
(n=231)
mPFS
7.3 months
3.5 months
HR=0.45 (95% CI: 0.34, 0.59)†; p<0.0001‡
13.2 months median OS with RASONQUE (95% CI: 10.0, NE) versus 6.7 months median OS with SOC combination chemotherapy (95% CI: 5.8, 8.0) in the ITT population. 60% reduction in the risk of death (HR=0.40 [95% CI: 0.30, 0.53]†; p<0.0001‡).
  • mPFS in the ITT population was 7.2 months with RASONQUE vs 3.6 months with SOC combination chemotherapy, HR=0.49 (95% CI: 0.38, 0.64)†; p<0.00011‡

RASolute 302 was a global, randomized, head-to-head, open-label, Phase 3 trial evaluating the efficacy and safety of RASONQUE monotherapy vs SOC combination chemotherapy in adult patients with metastatic pancreatic adenocarcinoma who had received at least 1 prior systemic therapy.1,2

*Including MedPlus Specialty Pharmacy in Puerto Rico. MedPlus can be contacted via phone at 787.523.3888 and by fax at 888.855.8865.

*SOC combination chemotherapy included gemcitabine + nab-paclitaxel, modified FOLFIRINOX, nal-IRI + FU/LV, and FOLFOX.

CI=confidence interval; HR=hazard ratio; ITT=intent-to-treat; mPDAC=metastatic pancreatic adenocarcinoma; PFS=progression-free survival; RAS=rat sarcoma; SOC=standard of care.

spacing-xs

*SOC combination chemotherapy included mFOLFIRINOX, gemcitabine + nab-paclitaxel, FOLFOX, or liposomal irinotecan + 5-FU/leucovorin.1

†Based on the stratified Cox proportional hazard model.1

‡Two-sided p-value based on stratified log-rank test.1,2

style
cobalt
without-image
Approved for all adult patients with mPDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy1
See the data
https://www.revmed.com/pi/us-rasonque-pi.pdf
spacing-lg
style
cobalt

RASONQUE is available

through select oncology-focused specialty pharmacies

NDC: 85219-101-01

30-count 100 mg tablets

NDC: 85219-104-01

30-count 150 mg tablets

spacing-md
Biologics by McKesson
Onco360 Oncology Pharmacy
Phone
1-800-850-4306
1-888-742-9307
Fax
1-800-823-4506
1-877-662-6355
Website
biologics.mckesson.com
onco360.com
NPI
1487640314
1437577988
spacing-md
*Including MedPlus Solutions in Puerto Rico. MedPlus can be contacted via phone at 1-787-523-3888 and by fax at 1-888-855-8865.
identifier
ordering-section
(ON)Path

Support that moves your patients forward

Enrolling in our Patient Support Program can help connect eligible patients with reimbursement services, commercial copay resources, and other patient assistance resources.*

We stay focused on access to treatment so your patients can focus on what matters to them.

Help keep your patients on the path to treatment.
Visit www.revmedonpath.com to enroll your patient online.

Have questions?
Call a Patient Access Advocate at 1-844-ONPATH0 (844-667-2840),
Monday-Friday, 8 AM to 8 PM EST

*Additional terms and conditions apply. Please visit www.revmedonpath.com for full terms and conditions or call a Patient Access Advocate at 1-844-ONPATH0 (844-667-2840).
style
cobalt
identifier
tablet-table

5-FU=5-fluorouracil; CI=confidence interval; FOLFOX=leucovorin + 5-FU + oxaliplatin; HR=hazard ratio; ITT=intent-to-treat; mFOLFIRINOX=modified leucovorin + 5-FU + irinotecan + oxaliplatin; mPFS=median progression-free survival; NE=not estimable; PFS=progression-free survival; RAS=rat sarcoma.

identifier
footnote-section

References: 1. RASONQUE. Prescribing information. Revolution Medicines, Inc.; 2026. 2. O’Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMoa2605555 3. Katayama ES, Hue JJ, Bajor DL, et al. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget. 2020;11(38):3489-3501. doi:10.18632/oncotarget.27727

identifier
references-section
/content/branded-hcp-na/isi-block
expandable
true
expandable-title
Expand
identifier
isi